about
PEGylation of protein-based MRI contrast agents improves relaxivities and biocompatibilitiesPEGylated Adenoviruses: From Mice to MonkeysImpact of pro segments on the folding and function of human neutrophil alpha-defensinsIn vitro and in vivo antimicrobial activity of granulysin-derived peptides against Vibrio choleraeAn orally delivered small-molecule formulation with antiangiogenic and anticancer activityNanotechnology, nanotoxicology, and neurosciencePotent D-peptide inhibitors of HIV-1 entryRecombinant human butyrylcholinesterase from milk of transgenic animals to protect against organophosphate poisoningMicromanaging cardiac regeneration: Targeted delivery of microRNAs for cardiac repair and regenerationOnto better TRAILs for cancer treatmentInhaled nano- and microparticles for drug deliveryAnti-PEG immunity: emergence, characteristics, and unaddressed questions.Exploiting nanotechnology to overcome tumor drug resistance: Challenges and opportunitiesBench-to-bedside translation of magnetic nanoparticlesAutomated solid-phase peptide synthesis to obtain therapeutic peptidesPolymer-drug conjugates: origins, progress to date and future directionsDesign Rationale and Development Approach for Pegfilgrastim as a Long-Acting Granulocyte Colony-Stimulating FactorNanotechnology in bone tissue engineeringCys34-PEGylated Human Serum Albumin for Drug Binding and DeliveryEZN-2208 (PEG-SN38) overcomes ABCG2-mediated topotecan resistance in BRCA1-deficient mouse mammary tumorsStealth filaments: Polymer chain length and conformation affect the in vivo fate of PEGylated potato virus X.N-terminal protein modification by substrate-activated reverse proteolysisStructure of a PEGylated protein reveals a highly porous double-helical assemblySynthesis and in Vitro and in Vivo Evaluation of MMP-12 Selective Optical ProbesPolyethylene glycols: An effective strategy for limiting liver ischemia reperfusion injuryVirus-Based Nanoparticles as Versatile NanomachinesTherapeutic and routine prophylactic properties of rFactor VIII Fc (efraloctocog alfa, Eloctate®) in hemophilia APEGylated Human Serum Albumin: Review of PEGylation, Purification and Characterization MethodsKey factors influencing ADME properties of therapeutic proteins: A need for ADME characterization in drug discovery and developmentCancer nanomedicine: from targeted delivery to combination therapyIntroducing genetically encoded aldehydes into proteinsPharmaceutical and toxicological properties of engineered nanomaterials for drug deliveryA porphodimethene chemical inhibitor of uroporphyrinogen decarboxylaseVirus-based nanomaterials as positron emission tomography and magnetic resonance contrast agents: from technology development to translational medicinePEGylation of Truncated Streptokinase Leads to Formulation of a Useful Drug with Ameliorated AttributesPEGylation potentiates the effectiveness of an antagonistic peptide that targets the EphB4 receptor with nanomolar affinityDiazo Compounds: Versatile Tools for Chemical BiologyPre-Assembly of Near-Infrared Fluorescent Multivalent Molecular Probes for Biological ImagingTrimethyl lock: a trigger for molecular release in chemistry, biology, and pharmacologyAlternative binding proteins: anticalins - harnessing the structural plasticity of the lipocalin ligand pocket to engineer novel binding activities.
P2860
Q24594884-0BE9DA7D-6E29-4111-82C0-4D29AD91B6CFQ24635276-C938F296-236B-4B15-8CF2-6A40F974BA86Q24644482-A3258E02-1B45-4A88-93D8-B2B202306AA5Q24647817-B39F21DB-B51B-4803-AB38-0AD04234B3A0Q24649290-713A0BE9-8D3C-44B9-B8E8-67D5D4627F9FQ24650444-B9299372-1CE7-41CF-9564-DF1BE618AC49Q24675493-40A60D23-F6BA-4EA0-BFD3-6B2061CB4786Q24683895-39B6FB2D-704E-4F88-B6FB-D6C0FD764492Q26765166-07A6B9EF-C2A1-477D-A1C8-2071F0B257E8Q26768160-0856907A-56C7-4413-9F2D-32DEDD68BE32Q26771328-1B5C4B2D-A027-4F3E-ABE1-CAD28CFAA13AQ26825556-25EA40B5-3777-4D28-B94F-BE90D79893ABQ26828930-ABE98097-16D9-4F0C-A53F-1360963B9722Q26850547-7ECF6CA6-C0E4-4330-9D2C-B9D3F76596CCQ27001623-E8AE3715-0DCD-40B5-B6FF-278AE687FC51Q27002505-FA773F61-A50D-4199-B5C4-A8A1CFD5E820Q27004054-67C50594-84E4-43CA-B124-891E13218085Q27008868-5D6DB2C2-2FFB-46CF-A819-C6121708DB87Q27301475-8796882A-A753-4ADC-A659-60FC1E30F158Q27318449-15B3EB6D-161B-45E8-9506-4DABD684F3D4Q27334548-14FE8DAE-0164-4D00-A8A6-3F1513945C2EQ27689065-D08846D1-CC9A-4A65-A17D-A44B2C4EDCF5Q27702190-05E52E42-30B2-4DA1-B581-3FA355F77288Q27727742-C2AE4349-E6F8-4DC6-A52E-91B2751AA9AFQ28066686-EF9DBC35-0D1A-4FC2-9456-D53098AF0D7FQ28068538-AF262872-36D2-49DD-B0C8-89B075F96247Q28075081-D24EBB98-FC65-4F17-AD74-BA701C03961CQ28076027-68C058C4-2C7F-42CA-89E0-C49D592C50B9Q28082880-9931BD6F-F642-4E49-A2CB-89C50475F89CQ28083065-A2C69C49-1BC5-4264-A506-7C1DC0453806Q28298867-4F4674E3-2EF6-4022-84D8-14737EEF5693Q28396383-38E2EB45-111C-4C99-AE7A-A03EC9D32BC3Q28540127-DF40ED2E-9B1E-47C7-8228-502C0AD14B0DQ28550482-A42FC987-C9A4-470E-A419-7E90A3CE819AQ28552198-AD18F664-40E7-4730-990B-BE75C0EF90B4Q28741459-E9310746-A980-4FB6-8DD4-7B967A52A507Q28817199-9807D5C3-D059-416B-ACB9-D9EA56723B88Q28829172-644CE195-6E00-4368-8FEF-3DB5F6555AB6Q29303893-10991D7A-CF18-4098-888A-728016BC49BEQ30157688-AC9337CA-F8B7-4AE2-B877-761D620BCB4E
P2860
description
2003 nî lūn-bûn
@nan
2003 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի մարտին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Effect of pegylation on pharmaceuticals.
@ast
Effect of pegylation on pharmaceuticals.
@en
type
label
Effect of pegylation on pharmaceuticals.
@ast
Effect of pegylation on pharmaceuticals.
@en
prefLabel
Effect of pegylation on pharmaceuticals.
@ast
Effect of pegylation on pharmaceuticals.
@en
P356
P1476
Effect of pegylation on pharmaceuticals.
@en
P2093
J Milton Harris
Robert B Chess
P2888
P304
P356
10.1038/NRD1033
P577
2003-03-01T00:00:00Z